{
  "success": true,
  "pagesUsed": [
    2,
    7,
    8
  ],
  "modelUsed": "claude-opus-4-5",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "Protocol Synopsis",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "Protocol Synopsis",
        "sectionType": {
          "code": "Synopsis",
          "codeSystem": "USDM",
          "decode": "Synopsis"
        }
      },
      {
        "id": "nc_2",
        "name": "Schedule of Activities",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "sectionType": {
          "code": "Study Procedures",
          "codeSystem": "USDM",
          "decode": "Study Procedures"
        }
      },
      {
        "id": "nc_3",
        "name": "Introduction",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "Introduction",
        "sectionType": {
          "code": "Introduction",
          "codeSystem": "USDM",
          "decode": "Introduction"
        },
        "childIds": [
          "nci_3_1",
          "nci_3_2",
          "nci_3_3"
        ]
      },
      {
        "id": "nc_4",
        "name": "Objectives and Endpoints",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "Objectives and Endpoints",
        "sectionType": {
          "code": "Objectives",
          "codeSystem": "USDM",
          "decode": "Objectives"
        }
      },
      {
        "id": "nc_5",
        "name": "Study Design",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "Study Design",
        "sectionType": {
          "code": "Study Design",
          "codeSystem": "USDM",
          "decode": "Study Design"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2",
          "nci_5_3",
          "nci_5_4",
          "nci_5_5"
        ]
      },
      {
        "id": "nc_6",
        "name": "Study Population",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "6",
        "sectionTitle": "Study Population",
        "sectionType": {
          "code": "Study Population",
          "codeSystem": "USDM",
          "decode": "Study Population"
        },
        "childIds": [
          "nci_6_1",
          "nci_6_2",
          "nci_6_3",
          "nci_6_4"
        ]
      },
      {
        "id": "nc_7",
        "name": "Treatment",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "sectionType": {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        },
        "childIds": [
          "nci_7_1",
          "nci_7_2"
        ]
      },
      {
        "id": "nc_8",
        "name": "Abbreviations and Definitions",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 1",
        "sectionTitle": "Abbreviations and Definitions",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_9",
        "name": "Clinical Laboratory Tests",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_10",
        "name": "Study Governance, Regulatory and Ethical Considerations",
        "order": 9,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 3",
        "sectionTitle": "Study Governance, Regulatory and Ethical Considerations",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_11",
        "name": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "order": 10,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_12",
        "name": "Blood Sampling Summary",
        "order": 11,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_13",
        "name": "Nasal and Non-nasal Score Questionnaire",
        "order": 12,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_14",
        "name": "Edinburgh Hypoglycemia Scale",
        "order": 13,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_15",
        "name": "Clarke Hypoglycemia Awareness Survey",
        "order": 14,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      },
      {
        "id": "nc_16",
        "name": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
        "order": 15,
        "instanceType": "NarrativeContent",
        "sectionNumber": "Appendix 9",
        "sectionTitle": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
        "sectionType": {
          "code": "Appendix",
          "codeSystem": "USDM",
          "decode": "Appendix"
        }
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_3_1",
        "name": "Study Rationale",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Study Rationale"
      },
      {
        "id": "nci_3_2",
        "name": "Background",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Background"
      },
      {
        "id": "nci_3_3",
        "name": "Benefit/Risk Assessment",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.3",
        "sectionTitle": "Benefit/Risk Assessment"
      },
      {
        "id": "nci_5_1",
        "name": "Overall Design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.1",
        "sectionTitle": "Overall Design"
      },
      {
        "id": "nci_5_2",
        "name": "Number of Participants",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.2",
        "sectionTitle": "Number of Participants"
      },
      {
        "id": "nci_5_3",
        "name": "End of Study Definition",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.3",
        "sectionTitle": "End of Study Definition"
      },
      {
        "id": "nci_5_4",
        "name": "Scientific Rationale for Study Design",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.4",
        "sectionTitle": "Scientific Rationale for Study Design"
      },
      {
        "id": "nci_5_5",
        "name": "Justification for Dose",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "5.5",
        "sectionTitle": "Justification for Dose"
      },
      {
        "id": "nci_6_1",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_6_2",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_6_3",
        "name": "Lifestyle and/or Dietary Requirements",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.3",
        "sectionTitle": "Lifestyle and/or Dietary Requirements"
      },
      {
        "id": "nci_6_4",
        "name": "Screen Failures",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.4",
        "sectionTitle": "Screen Failures"
      },
      {
        "id": "nci_7_1",
        "name": "Treatment Administered",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "7.1",
        "sectionTitle": "Treatment Administered"
      },
      {
        "id": "nci_7_2",
        "name": "Method of Treatment Assignment",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "7.2",
        "sectionTitle": "Method of Treatment Assignment"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "AE",
        "expandedText": "adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "AUC",
        "expandedText": "area under the concentration versus time curve",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "BGmax",
        "expandedText": "maximal plasma glucose concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "Cmax",
        "expandedText": "maximal concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "IMG",
        "expandedText": "intramuscular glucagon",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "IM",
        "expandedText": "intramuscular",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "PD",
        "expandedText": "pharmacodynamics",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "PG",
        "expandedText": "plasma glucose",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "PK",
        "expandedText": "pharmacokinetics",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "SAE",
        "expandedText": "serious adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "TEAE",
        "expandedText": "treatment-emergent adverse event",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "Tmax",
        "expandedText": "time to maximal concentration",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "T1DM",
        "expandedText": "type 1 diabetes mellitus",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "T2DM",
        "expandedText": "type 2 diabetes mellitus",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 16,
      "itemCount": 14,
      "abbreviationCount": 14
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "a",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9",
        "nc_10",
        "nc_11",
        "nc_12",
        "nc_13",
        "nc_14",
        "nc_15",
        "nc_16"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "AE",
          "expansion": "adverse event"
        },
        {
          "abbreviation": "AUC",
          "expansion": "area under the concentration versus time curve"
        },
        {
          "abbreviation": "BGmax",
          "expansion": "maximal plasma glucose concentration"
        },
        {
          "abbreviation": "Cmax",
          "expansion": "maximal concentration"
        },
        {
          "abbreviation": "IMG",
          "expansion": "intramuscular glucagon"
        },
        {
          "abbreviation": "IM",
          "expansion": "intramuscular"
        },
        {
          "abbreviation": "PD",
          "expansion": "pharmacodynamics"
        },
        {
          "abbreviation": "PG",
          "expansion": "plasma glucose"
        },
        {
          "abbreviation": "PK",
          "expansion": "pharmacokinetics"
        },
        {
          "abbreviation": "SAE",
          "expansion": "serious adverse event"
        },
        {
          "abbreviation": "TEAE",
          "expansion": "treatment-emergent adverse event"
        },
        {
          "abbreviation": "Tmax",
          "expansion": "time to maximal concentration"
        },
        {
          "abbreviation": "T1DM",
          "expansion": "type 1 diabetes mellitus"
        },
        {
          "abbreviation": "T2DM",
          "expansion": "type 2 diabetes mellitus"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
        "version": "a",
        "versionDate": null
      },
      "sections": [
        {
          "number": "1",
          "title": "Protocol Synopsis",
          "type": "Synopsis"
        },
        {
          "number": "2",
          "title": "Schedule of Activities",
          "type": "Study Procedures"
        },
        {
          "number": "3",
          "title": "Introduction",
          "type": "Introduction",
          "subsections": [
            {
              "number": "3.1",
              "title": "Study Rationale"
            },
            {
              "number": "3.2",
              "title": "Background"
            },
            {
              "number": "3.3",
              "title": "Benefit/Risk Assessment"
            }
          ]
        },
        {
          "number": "4",
          "title": "Objectives and Endpoints",
          "type": "Objectives"
        },
        {
          "number": "5",
          "title": "Study Design",
          "type": "Study Design",
          "subsections": [
            {
              "number": "5.1",
              "title": "Overall Design"
            },
            {
              "number": "5.2",
              "title": "Number of Participants"
            },
            {
              "number": "5.3",
              "title": "End of Study Definition"
            },
            {
              "number": "5.4",
              "title": "Scientific Rationale for Study Design"
            },
            {
              "number": "5.5",
              "title": "Justification for Dose"
            }
          ]
        },
        {
          "number": "6",
          "title": "Study Population",
          "type": "Study Population",
          "subsections": [
            {
              "number": "6.1",
              "title": "Inclusion Criteria"
            },
            {
              "number": "6.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "6.3",
              "title": "Lifestyle and/or Dietary Requirements",
              "subsections": [
                {
                  "number": "6.3.1",
                  "title": "Meals and Dietary Restrictions"
                },
                {
                  "number": "6.3.2",
                  "title": "Caffeine, Alcohol, and Tobacco"
                },
                {
                  "number": "6.3.3",
                  "title": "Activity"
                },
                {
                  "number": "6.3.4",
                  "title": "Contraception"
                }
              ]
            },
            {
              "number": "6.4",
              "title": "Screen Failures"
            }
          ]
        },
        {
          "number": "7",
          "title": "Treatment",
          "type": "Treatment",
          "subsections": [
            {
              "number": "7.1",
              "title": "Treatment Administered",
              "subsections": [
                {
                  "number": "7.1.1",
                  "title": "Packaging and Labeling"
                },
                {
                  "number": "7.1.2",
                  "title": "Medical Devices"
                }
              ]
            },
            {
              "number": "7.2",
              "title": "Method of Treatment Assignment"
            }
          ]
        },
        {
          "number": "Appendix 1",
          "title": "Abbreviations and Definitions",
          "type": "Appendix"
        },
        {
          "number": "Appendix 2",
          "title": "Clinical Laboratory Tests",
          "type": "Appendix"
        },
        {
          "number": "Appendix 3",
          "title": "Study Governance, Regulatory and Ethical Considerations",
          "type": "Appendix"
        },
        {
          "number": "Appendix 4",
          "title": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
          "type": "Appendix"
        },
        {
          "number": "Appendix 5",
          "title": "Blood Sampling Summary",
          "type": "Appendix"
        },
        {
          "number": "Appendix 6",
          "title": "Nasal and Non-nasal Score Questionnaire",
          "type": "Appendix"
        },
        {
          "number": "Appendix 7",
          "title": "Edinburgh Hypoglycemia Scale",
          "type": "Appendix"
        },
        {
          "number": "Appendix 8",
          "title": "Clarke Hypoglycemia Awareness Survey",
          "type": "Appendix"
        },
        {
          "number": "Appendix 9",
          "title": "Protocol Amendment I8R-JE-IGBJ(a) Summary A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients with Diabetes Mellitus",
          "type": "Appendix"
        }
      ]
    }
  }
}